BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 29138285)

  • 21. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.
    Blank S; Rachakonda S; Keller G; Weichert W; Lordick F; Langer R; Springfeld C; Bruckner T; Becker K; Kumar R; Ott K
    BMC Cancer; 2014 Feb; 14():58. PubMed ID: 24490800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
    Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
    Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical significance of human epidermal growth factor receptor family molecules expression in gastric cancer].
    Li G; Gu RM; Wen X; Ming XZ; Xia L; Xu XY; Zhang J; Chen HQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jul; 16(7):668-72. PubMed ID: 23888453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of HER-2 Protein is a High-Risk Factor for Patients with Surgically-Resected Stage T3 Gastric Adenocarcinoma.
    Zhang Z; Wang B; Huang G; Wang R; Song J; Lin S; Wang W; Jiang Y; Huang Q; Wang L
    Clin Lab; 2017 Jan; 63(1):115-125. PubMed ID: 28164509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of biological markers of epithelial to mesenchymal transition in oesophageal adenocarcinoma, an immunohistochemical study.
    Prins MJ; Ruurda JP; Lolkema MP; Sitarz R; Ten Kate FJ; van Hillegersberg R
    J Clin Pathol; 2015 Jul; 68(7):529-35. PubMed ID: 25855799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
    van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
    Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
    Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
    Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
    Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
    Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas.
    Paliga A; Marginean H; Tessier-Cloutier B; Purgina B; Jonker D; Marginean EC
    Am J Clin Oncol; 2017 Dec; 40(6):543-551. PubMed ID: 26125303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study.
    Nagaraja V; Shaw N; Morey AL; Cox MR; Eslick GD
    Eur J Surg Oncol; 2016 Jan; 42(1):140-8. PubMed ID: 26422587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High expression of HER3 is associated with a decreased survival in gastric cancer.
    Hayashi M; Inokuchi M; Takagi Y; Yamada H; Kojima K; Kumagai J; Kawano T; Sugihara K
    Clin Cancer Res; 2008 Dec; 14(23):7843-9. PubMed ID: 19047113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.
    Shen GS; Zhao JD; Zhao JH; Ma XF; Du F; Kan J; Ji FX; Ma F; Zheng FC; Wang ZY; Xu BH
    World J Gastroenterol; 2016 Jun; 22(23):5406-14. PubMed ID: 27340357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
    Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
    BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.
    Ott K; Blank S; Becker K; Langer R; Weichert W; Roth W; Sisic L; Stange A; Jäger D; Büchler M; Siewert JR; Lordick F
    Langenbecks Arch Surg; 2013 Feb; 398(2):239-49. PubMed ID: 23269519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.
    Sato Y; Inokuchi M; Takagi Y; Otsuki S; Fujimori Y; Yanaka Y; Kobayashi K; Higuchi K; Kojima K; Kawano T
    J Clin Pathol; 2015 Oct; 68(10):795-801. PubMed ID: 26043748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
    Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
    Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma.
    Cabau M; Luc G; Terrebonne E; Belleanne G; Vendrely V; Sa Cunha A; Collet D
    Am J Surg; 2013 Jun; 205(6):711-7. PubMed ID: 23422318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.